SS-31 (Elamipretide) Complete Research

SS-31 (Elamipretide) Complete Research Guide

Among mitochondria-targeting research compounds, SS-31 — also known as Elamipretide, MTP-131, or Bendavia — occupies a distinctive position. Rather than acting as a broad antioxidant or a signalling molecule that indirectly influences mitochondrial function, SS-31 was purpose-engineered to selectively accumulate at a single, precisely defined molecular target: cardiolipin, the signature phospholipid of the inner mitochondrial membrane. This guide provides a complete standalone overview of SS-31's structure, mechanism, research applications, and laboratory handling.

All content is for educational and research purposes only. SS-31 is designated for research use only and is not approved for human or veterinary use.

What Is SS-31?

SS-31 is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-2'6'-Dmt-Lys-Phe-NH2. Its molecular weight is approximately 639.8 g/mol. It belongs to the "Szeto-Schiller" (SS) peptide class, developed specifically to selectively target mitochondrial membranes rather than acting as a generic cell-permeable compound.

  • Molecular formula: C₃₆H₄₉N₉O₅
  • Molecular weight: ~639.8 g/mol
  • Structure: Alternating aromatic and cationic amino acid residues
  • Supply form: Lyophilized powder, ≥99% purity

Proto Peptide supplies SS-31 10mg for research use across Canada and the USA.

The Design Principle: Selective Mitochondrial Targeting

What makes SS-31 mechanistically distinctive is its structural design. The alternating pattern of aromatic (2'6'-dimethyltyrosine, phenylalanine) and cationic (D-arginine, lysine) residues gives the peptide two key properties:

Cell permeability without electrical dependence: Unlike many mitochondria-targeted compounds (such as MitoQ or various triphenylphosphonium-conjugated antioxidants) that rely on the mitochondrial membrane potential to accumulate in the mitochondrial matrix, SS-31 accumulates at the inner mitochondrial membrane independent of membrane potential. This is a critical distinction — in disease and injury states where membrane potential is already compromised, potential-dependent compounds lose their targeting efficiency, whereas SS-31's targeting is preserved.

Selective cardiolipin binding: The aromatic-cationic motif allows SS-31 to bind selectively to cardiolipin, an anionic phospholipid found almost exclusively in the inner mitochondrial membrane (IMM) and essentially absent from other cellular membranes. This selectivity means SS-31 concentrates specifically where cardiolipin resides, rather than distributing broadly across cellular membranes.

Cardiolipin: Why This Target Matters

Cardiolipin is a unique, doubly-anionic phospholipid comprising a significant fraction of the IMM's lipid content. Its function extends well beyond structural membrane composition:

Cytochrome c anchoring: Cardiolipin binds and anchors cytochrome c — a critical electron transport chain (ETC) component — to the IMM in proximity to Complex III and Complex IV. This positioning is essential for efficient electron transfer during oxidative phosphorylation.

ETC supercomplex assembly: Cardiolipin facilitates the assembly of ETC complexes into "supercomplexes" or respirasomes — higher-order structural arrangements of Complexes I, III, and IV that improve electron transport efficiency and reduce electron leakage.

Cristae architecture: Cardiolipin's cone-shaped molecular geometry contributes to the curvature of the IMM's cristae folds, which maximise the membrane surface area available for ETC complexes and ATP synthase.

What Happens When Cardiolipin Is Damaged

Cardiolipin is particularly susceptible to peroxidation by reactive oxygen species (ROS) due to its high content of unsaturated fatty acid chains. When ROS-mediated cardiolipin peroxidation occurs — as happens during ischaemia-reperfusion injury, chronic oxidative stress, aging, and various disease states — several downstream consequences follow:

  1. Cytochrome c release: Damaged cardiolipin loses its ability to anchor cytochrome c, which can then be released — first into the intermembrane space, then potentially into the cytoplasm, where it triggers apoptotic signalling
  2. ETC supercomplex disassembly: Loss of cardiolipin's structural support disrupts respirasome assembly, reducing electron transport efficiency
  3. Increased electron leakage: Disassembled, inefficient ETC complexes leak more electrons prematurely, generating additional ROS — creating a self-reinforcing cycle of damage
  4. Reduced ATP production: The net effect of all the above is impaired oxidative phosphorylation capacity and reduced cellular ATP availability

SS-31's selective binding to cardiolipin is thought to stabilise this critical phospholipid against peroxidation, preserving cytochrome c anchoring, ETC supercomplex integrity, and ultimately mitochondrial bioenergetic function even under oxidative stress conditions.

Research Applications

Ischaemia-Reperfusion Injury

This is SS-31's most extensively studied research application. When blood flow is restored after a period of ischaemia (in cardiac, renal, cerebral, or limb models), the sudden reintroduction of oxygen produces a burst of ROS that damages cardiolipin and triggers the cascade described above. SS-31 administered before or during early reperfusion has been documented in preclinical models to preserve mitochondrial membrane integrity, reduce infarct size, and improve functional recovery in cardiac ischaemia-reperfusion models.

Heart Failure Research

Cardiomyocytes are exceptionally mitochondria-dense given the heart's continuous energy demands. In heart failure models, mitochondrial dysfunction — including cardiolipin abnormalities — contributes to impaired cardiac energetics. SS-31 has been studied for its capacity to preserve mitochondrial function and improve cardiac contractile performance in various heart failure models, including pressure-overload and genetic models of cardiomyopathy.

Renal Research

The kidney's high metabolic demand makes it particularly vulnerable to mitochondrial dysfunction. SS-31 has been studied in acute kidney injury models (including ischaemia-reperfusion-induced AKI) and chronic kidney disease models, with documented preservation of renal mitochondrial structure and function, and reduced markers of tubular injury.

Neurodegenerative Disease Models

Mitochondrial dysfunction — including cardiolipin abnormalities — is implicated in the pathophysiology of Parkinson's disease, Alzheimer's disease, and ALS. SS-31's neuroprotective effects in relevant animal models have been documented, with proposed mechanisms centred on preserved mitochondrial bioenergetics in neurons, which are particularly dependent on efficient ATP production given their high energy demands and limited capacity for glycolytic ATP generation.

Skeletal Muscle and Sarcopenia Research

Age-related muscle mitochondrial dysfunction contributes to sarcopenia (age-related muscle loss). SS-31 has been studied in aged animal models for its effects on skeletal muscle mitochondrial function, muscle fatigue resistance, and exercise capacity — an application area that connects to broader aging biology research.

Ophthalmological Research

Retinal tissue has exceptionally high mitochondrial density and oxygen demand, making it vulnerable to mitochondrial dysfunction. SS-31 has been investigated in models of retinal degeneration and age-related macular degeneration-relevant pathways, given the retina's dependence on efficient mitochondrial function for photoreceptor maintenance.

SS-31 in the Context of Other Mitochondrial Research Compounds

SS-31's mechanism — structural protection of the inner mitochondrial membrane — is distinct from other mitochondrial compounds in the Proto Peptide catalog:

vs. MOTS-C: MOTS-C activates AMPK and drives mitochondrial biogenesis through nuclear gene regulation — creating new mitochondrial capacity. SS-31 protects existing mitochondria from membrane damage. See our SS-31 vs. MOTS-C comparison for the complete mechanistic breakdown.

vs. NAD+: NAD+ serves as the electron carrier substrate for the ETC and the co-substrate for sirtuin enzymes — supporting the biochemical reactions of oxidative phosphorylation and its regulatory network. SS-31 protects the physical membrane infrastructure in which those reactions occur.

vs. SLU-PP-332: SLU-PP-332 activates ERR transcription factors to drive mitochondrial biogenesis and oxidative gene expression — again, a capacity-building mechanism distinct from SS-31's membrane-protective mechanism.

For comprehensive mitochondrial research designs, SS-31 is frequently considered alongside these compounds as a complementary rather than redundant tool — addressing membrane protection where the others address capacity and substrate availability.

Laboratory Handling

SS-31 is water-soluble and reconstitutes readily in sterile bacteriostatic water.

Reconstitution Protocol

  1. Equilibrate sealed vial to room temperature (15–30 minutes from freezer)
  2. Wipe stopper with 70% isopropyl alcohol; allow 30 seconds to dry
  3. Draw the target volume of bacteriostatic water using a sterile syringe
  4. Inject slowly down the inner vial wall
  5. Swirl gently until fully dissolved; inspect for clarity

Storage

  • Lyophilized: -20°C, dark and dry environment, 24+ months shelf life
  • Reconstituted: 2–8°C, 4–6 weeks; aliquot into single-use portions to avoid freeze-thaw cycling

Use Proto Peptide's Bacteriostatic Water (Hospira 30mL) and Syringe Bundle for reconstitution and injection supplies.

Frequently Asked Questions

Why is SS-31 also called Elamipretide or MTP-131? These are alternative names used across different stages of its research and development history. "SS-31" reflects its origin in the Szeto-Schiller peptide series; "Elamipretide" and "MTP-131" are names used in later-stage research and development contexts. All refer to the same molecular compound.

Does SS-31 need mitochondrial membrane potential to work, unlike other mitochondria-targeted compounds? No — this is one of SS-31's key mechanistic advantages. Unlike triphenylphosphonium-based mitochondria-targeted compounds that rely on the membrane potential (which can itself be compromised in disease states) to accumulate in mitochondria, SS-31 binds cardiolipin directly and independent of membrane potential.

Is SS-31 an antioxidant? SS-31's primary documented mechanism is structural protection of cardiolipin from peroxidation, which secondarily reduces the ROS generated by dysfunctional ETC supercomplexes. This is mechanistically distinct from — though functionally related to — classical direct free-radical-scavenging antioxidants.

What tissue types is SS-31 most relevant to? Tissues with high mitochondrial density and energy demand are of greatest research interest: cardiac muscle, skeletal muscle, kidney, brain/CNS, and retina.

Conclusion

SS-31's precisely engineered mechanism — selective, membrane-potential-independent binding to cardiolipin — makes it one of the most mechanistically specific tools available for mitochondrial membrane research. By protecting the structural integrity of cardiolipin, SS-31 preserves cytochrome c anchoring, ETC supercomplex assembly, and ultimately oxidative phosphorylation capacity under oxidative stress conditions relevant to ischaemia-reperfusion injury, heart failure, kidney disease, neurodegeneration, and aging research.

Proto Peptide supplies SS-31 10mg at ≥99% HPLC-verified purity for Canadian and US research use. Browse our full catalog for our complete mitochondrial research compound range.

Where to Buy Research-Grade Peptides in Canada and the USA

If you are sourcing high-purity research peptides, quality matters.

At Proto Peptide, we provide research-grade compounds including:

We ship across Canada and to the United States, offering reliable fulfillment and clearly labeled research products.

Shipping & support

We ship to Canadian research addresses and provide documentation (COA/COC) on request. If you need help with storage or dosing for in-lab protocols, check out our Reconstitution Guide and Peptide Storing Guide

Disclaimer

This content is intended for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves. Always follow your institution’s guidelines and consult safety data sheets (SDS) before handling any research chemical.

Back to blog